7 Takeaways From the JPMorgan Healthcare Conference
In contrast to every other year, it was rare to hear a management team say, "I think we're undervalued."
This was my eleventh JPM conference, but first from the buy side. It was an interesting experience being on this side, and one I thoroughly enjoyed. The week is always a bit of a blur (I had over 60 meetings and presentations on my calendar in addition to the late-night "events"), but I did have a few takeaways I thought worth sharing with Minyanville readers.
The highest-flying small-/mid-cap biotechs usually have least 2014 data.This suggests the fast-money types may rotate out of these stocks until later in the year.
In big contrast to every other year, I rarely heard a management team say, "I think we're undervalued."
Intercept Pharma’s (NASDAQ:ICPT) consecutive $203 and $167 gain days (no, not percent – dollars per share) scared the jeepers out of “casual” biotech bears. I expect some of the biotech sector gains thus far in 2014 are directly related to risk management officers in funds taking a real hard look at any proposal to short low-float names – which describes all the recent IPOs and most of the sector’s highest fliers. This might be a durable situation.
By virtue of the Alnylam (NASDAQ:ALNY) twin deals, siRNA got added to the more predictable list of CAR-T immunotherapy, checkpoint inhibitor immunotherapy, and cancer stem cell drugs as predictable hot-product areas for 2014.
Since I joined just after the 2010 iteration of JPMorgan’s conference, Twitter (NYSE:TWTR) has been a hugely important tool. This year’s hashtag feed (#JPM14) was less useful than any prior year, however. Too much noise. That’s not to say my feed was useless. By following the right group, you get critically important insights from very smart people.
It’s always a sport to guess the mood of the crowd and apply that to some prognostication for the coming year’s performance. I’m not sure that’s useful, but there was no reason to not have a good time at the event this year. Everyone was upbeat, positive -- and not just because of the gains seen in 2013.
Biotech companies are making real progress in cancer and orphan diseases. Narrowing drug development to targeted markets is making a huge difference. Nearly a decade after I penned Death of the Blockbuster Drug, the idea of targeted therapies is dominant.
Follow the markets all day every day with a FREE 14 day trial to Buzz & Banter. Over 30 professional traders share their ideas in real-time. Learn more.
The information on this website solely reflects the analysis of or opinion about the performance of securities and financial markets by the writers whose articles appear on the site. The views expressed by the writers are not necessarily the views of Minyanville Media, Inc. or members of its management. Nothing contained on the website is intended to constitute a recommendation or advice addressed to an individual investor or category of investors to purchase, sell or hold any security, or to take any action with respect to the prospective movement of the securities markets or to solicit the purchase or sale of any security. Any investment decisions must be made by the reader either individually or in consultation with his or her investment professional. Minyanville writers and staff may trade or hold positions in securities that are discussed in articles appearing on the website. Writers of articles are required to disclose whether they have a position in any stock or fund discussed in an article, but are not permitted to disclose the size or direction of the position. Nothing on this website is intended to solicit business of any kind for a writer's business or fund. Minyanville management and staff as well as contributing writers will not respond to emails or other communications requesting investment advice.
Copyright 2011 Minyanville Media, Inc. All Rights Reserved.